NEW YORK, Nov. 28 - IBM and Lion Bioscience said on Wednesday that they signed a deal to combine their technologies and jointly market the new offering.
Under the terms of the deal, which was anticipated by GenomeWeb several weeks ago, the companies will combine Lion's SRS data integration platform with IBM's DiscoveryLink data integration software and services.
IBM, of Armonk, NY, will also offer Lion's technologies as part of its own hardware and middleware, including its WebSphere Internet software.
Lion, meanwhile, will use the combined technologies in its drug-discovery efforts at its headquarters in Heidelberg, Germany.
The companies said that the integration of their platforms was designed to give users a system that can integrate a range of scientific data that comes from different sources and in different file formats.
The alliance "will benefit researchers around the world by creating a rock-solid IT foundation for advanced research and development," Caroline Kovac, general manager of IBM Life Sciences, said in a statement. "The synergy between our technologies will put drug discovery on a faster track and give our mutual global customers unprecedented access to scientific data and advanced tools for knowledge management, data integration and collaboration."
Friedrich von Bohlen, Lion's CEO, said: "Together, we will provide customers, as well as our internal drug discovery unit, with the ultimate IT-driven solution to improve performance of the entire R&D chain in the industry."
Specifically, DiscoveryLink data integration software will be linked to SRS, which provides access to more than 450 public and private databases, including GenBank, Medline, and SwissProt. Both technologies are designed to allow users to obtain data from a number of sources with a single query.
SRS and DiscoveryLink also use a "federated data" approach, which allows data to remain in its original format and location while queries are executed across those databases and results are returned in a single file.
Financial terms of the deal were not disclosed.